Posted by Michael Wonder on 28 Feb 2022
PHARMAC ensures earlier access to key COVID-19 treatment
28 February 2022 - The access criteria for remdesivir is being temporarily widened to allow hospitals to treat those with mild to moderate symptoms of COVID-19, who are at high risk of severe disease, as of today.
“We initially purchased remdesivir to treat people hospitalised with moderate to severe COVID‑19,” says Pharmac’s Chief Medical Officer Dr David Hughes. “It was one of the first treatment options available for COVID-19 in New Zealand, and hospitals have been using it to treat patients who met certain access criteria.”
